91 related articles for article (PubMed ID: 11724232)
1. Novel malonamide derivatives as alpha v beta 3 antagonists. Syntheses and evaluation of 3-(3-indolin-1-yl-3-oxopropanoyl)aminopropanoic acids on vitronectin interaction with alpha v beta 3.
Nagashima S; Akamatsu S; Kawaminami E; Kawazoe S; Ogami T; Matsumoto Y; Okada M; Suzuki KI; Tsukamoto SI
Chem Pharm Bull (Tokyo); 2001 Nov; 49(11):1420-32. PubMed ID: 11724232
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel short chain 4-substituted indoles as potent alphavbeta3 antagonist using structure-based drug design.
Raboisson P; Desjarlais RL; Reed R; Lattanze J; Chaikin M; Manthey CL; Tomczuk BE; Marugán JJ
Eur J Med Chem; 2007 Mar; 42(3):334-43. PubMed ID: 17184884
[TBL] [Abstract][Full Text] [Related]
3. A concise synthesis and evaluation of new malonamide derivatives as potential α-glucosidase inhibitors.
Islam MS; Barakat A; Al-Majid AM; Ghabbour HA; Rahman AF; Javaid K; Imad R; Yousuf S; Choudhary MI
Bioorg Med Chem; 2016 Apr; 24(8):1675-82. PubMed ID: 26972921
[TBL] [Abstract][Full Text] [Related]
4. Novel potent and selective alphavbeta3/alphavbeta5 integrin dual antagonists with reduced binding affinity for human serum albumin.
Raboisson P; Manthey CL; Chaikin M; Lattanze J; Crysler C; Leonard K; Pan W; Tomczuk BE; Marugán JJ
Eur J Med Chem; 2006 Jul; 41(7):847-61. PubMed ID: 16697080
[TBL] [Abstract][Full Text] [Related]
5. Nonpeptide alphavbeta3 antagonists. Part 11: discovery and preclinical evaluation of potent alphavbeta3 antagonists for the prevention and treatment of osteoporosis.
Coleman PJ; Brashear KM; Askew BC; Hutchinson JH; McVean CA; Duong LT; Feuston BP; Fernandez-Metzler C; Gentile MA; Hartman GD; Kimmel DB; Leu CT; Lipfert L; Merkle K; Pennypacker B; Prueksaritanont T; Rodan GA; Wesolowski GA; Rodan SB; Duggan ME
J Med Chem; 2004 Sep; 47(20):4829-37. PubMed ID: 15369386
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and SAR of N-substituted dibenzazepinone derivatives as novel potent and selective alpha(V)beta(3) antagonists.
Kling A; Backfisch G; Delzer J; Geneste H; Graef C; Holzenkamp U; Hornberger W; Lange UE; Lauterbach A; Mack H; Seitz W; Subkowski T
Bioorg Med Chem Lett; 2002 Feb; 12(3):441-6. PubMed ID: 11814816
[TBL] [Abstract][Full Text] [Related]
7. Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrins.
De Corte BL; Kinney WA; Liu L; Ghosh S; Brunner L; Hoekstra WJ; Santulli RJ; Tuman RW; Baker J; Burns C; Proost JC; Tounge BA; Damiano BP; Maryanoff BE; Johnson DL; Galemmo RA
Bioorg Med Chem Lett; 2004 Oct; 14(20):5227-32. PubMed ID: 15380233
[TBL] [Abstract][Full Text] [Related]
8. Non-peptide alpha(v)beta(3) antagonists. Part 3: identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacements.
Coleman PJ; Brashear KM; Hunt CA; Hoffman WF; Hutchinson JH; Breslin MJ; McVean CA; Askew BC; Hartman GD; Rodan SB; Rodan GA; Leu CT; Prueksaritanont T; Fernandez-Metzler C; Ma B; Libby LA; Merkle KM; Stump GL; Wallace AA; Lynch JJ; Lynch R; Duggan ME
Bioorg Med Chem Lett; 2002 Jan; 12(1):31-4. PubMed ID: 11738567
[TBL] [Abstract][Full Text] [Related]
9. Non-peptide alpha(v)beta(3) antagonists. Part 5: identification of potent RGD mimetics incorporating 2-aryl beta-amino acids as aspartic acid replacements.
Brashear KM; Hunt CA; Kucer BT; Duggan ME; Hartman GD; Rodan GA; Rodan SB; Leu CT; Prueksaritanont T; Fernandez-Metzler C; Barrish A; Homnick CF; Hutchinson JH; Coleman PJ
Bioorg Med Chem Lett; 2002 Dec; 12(23):3483-6. PubMed ID: 12419389
[TBL] [Abstract][Full Text] [Related]
10. Alphavbeta3 integrin binding affinity and specificity of SM256 in various species.
Mousa SA; Lorelli W; Mohamed S; Batt DG; Jadhav PK; Reilly TM
J Cardiovasc Pharmacol; 1999 Apr; 33(4):641-6. PubMed ID: 10218736
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and initial evaluation of novel, non-peptidic antagonists of the alpha(v)-integrins alpha(v)beta(3) and alpha(v)beta(5).
Letourneau JJ; Liu J; Ohlmeyer MH; Riviello C; Rong Y; Li H; Appell KC; Bansal S; Jacob B; Wong A; Webb ML
Bioorg Med Chem Lett; 2009 Jan; 19(2):352-5. PubMed ID: 19081719
[TBL] [Abstract][Full Text] [Related]
12. Novel malonamide derivatives as potent kappa opioid receptor agonists.
Chu GH; Gu M; Cassel JA; Belanger S; Graczyk TM; DeHaven RN; Conway-James N; Koblish M; Little PJ; DeHaven-Hudkins DL; Dolle RE
Bioorg Med Chem Lett; 2007 Apr; 17(7):1951-5. PubMed ID: 17307360
[TBL] [Abstract][Full Text] [Related]
13. Nonpeptide alpha(v)beta(3) antagonists. Part 2: constrained glycyl amides derived from the RGD tripeptide.
Meissner RS; Perkins JJ; Duong LT; Hartman GD; Hoffman WF; Huff JR; Ihle NC; Leu CT; Nagy RM; Naylor-Olsen A; Rodan GA; Rodan SB; Whitman DB; Wesolowski GA; Duggan ME
Bioorg Med Chem Lett; 2002 Jan; 12(1):25-9. PubMed ID: 11738566
[TBL] [Abstract][Full Text] [Related]
14. 8-(1H-imidazol-1-yl)-7-nitro-4(5H)-imidazo[1,2-alpha]quinoxalinone and related compounds: synthesis and structure-activity relationships for the AMPA-type non-NMDA receptor.
Ohmori J; Shimizu-Sasamata M; Okada M; Sakamoto S
J Med Chem; 1997 Jun; 40(13):2053-63. PubMed ID: 9207947
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of integrin antagonists containing trans- and cis-2,5-disubstituted THF rings.
Osterkamp F; Ziemer B; Koert U; Wiesner M; Raddatz P; Goodman SL
Chemistry; 2000 Feb; 6(4):666-83. PubMed ID: 10807178
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of novel potent and selective alphavbeta3/alphavbeta5 integrin dual inhibitors with improved bioavailability. Selection of the molecular core.
Marugán JJ; Manthey C; Anaclerio B; Lafrance L; Lu T; Markotan T; Leonard KA; Crysler C; Eisennagel S; Dasgupta M; Tomczuk B
J Med Chem; 2005 Feb; 48(4):926-34. PubMed ID: 15715463
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist.
Kumar CC; Malkowski M; Yin Z; Tanghetti E; Yaremko B; Nechuta T; Varner J; Liu M; Smith EM; Neustadt B; Presta M; Armstrong L
Cancer Res; 2001 Mar; 61(5):2232-8. PubMed ID: 11280792
[TBL] [Abstract][Full Text] [Related]
18. [Studies on the synthesis of cholecystokinin A receptor antagonists. I. synthesis and cholecystokinin A receptor inhibitory activities of malonamide derivatives].
Ajisawa Y; Kitazawa M; Uchida M; Kobayashi M
Yakugaku Zasshi; 1996 Jan; 116(1):50-8. PubMed ID: 8699319
[TBL] [Abstract][Full Text] [Related]
19. Cyclic RGD peptidomimetics containing 4- and 5-amino-cyclopropane pipecolic acid (CPA) templates as dual αVβ3 and α5β1 integrin ligands.
Sernissi L; Trabocchi A; Scarpi D; Bianchini F; Occhiato EG
Bioorg Med Chem; 2016 Feb; 24(4):703-11. PubMed ID: 26753814
[TBL] [Abstract][Full Text] [Related]
20. Isoxazolines as potent antagonists of the integrin alpha(v)beta(3).
Pitts WJ; Wityak J; Smallheer JM; Tobin AE; Jetter JW; Buynitsky JS; Harlow PP; Solomon KA; Corjay MH; Mousa SA; Wexler RR; Jadhav PK
J Med Chem; 2000 Jan; 43(1):27-40. PubMed ID: 10633036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
